Drug-device Combination Products Market Outlook 2028

  • The global drug-device combination products market was valued at US$ 120 Bn in 2020
  • It is estimated to expand at a CAGR of 7.3% from 2021 to 2028
  • The global drug-device combination products market is expected to reach the value of US$ 221 Bn by the end of 2028

Analysts’ Viewpoint on Drug-device Combination Products Market Scenario

High incidence rates of chronic pain causing diseases are key drivers for the global drug-device combination products market. Initiatives by governments and NGOs to promote drug delivery implants, rising number of interventional cardiologists, and increasing demand for minimally invasive surgeries are some of the other factors propelling the growth of the drug-device combination products market. The introduction of biodegradable drug delivery technologies will serve as future growth opportunities for various drug-device combination products. However, product recalls act as a major growth restraint for the market due to incidences such as adverse side effects to patients. These products form a challenge to FDA, due to their classification overlapping regulated products and thus, complicating their approval process.

Increase in Prevalence of Chronic Diseases to Drive Global Market

The rising incidence of chronic diseases such as chronic diseases and disorders, including cancer, diabetic retinopathy, cardiovascular diseases, colorectal cancer, asthma, and obesity, cardiac conditions, multiple sclerosis, etc. is a major factor expected to drive the global drug-device combination products market. Millions of people are suffering from chronic diseases across the globe. The rising geriatric population across the globe is also an important factor contributing to the market growth.

The major product types in the market include drug eluting stents, infusion pumps, photosensitizers, orthopedic combination products, wound care combination products, inhalers, transdermal patches, and others, which include intraocular implants and drug eluting beads. Growth of home-based healthcare industry and technological advancements such as development of prefilled syringes also contribute to market growth.

Request a sample to get extensive insights into the Drug-device Combination Products Market

Transdermal Patches to Create Lucrative Opportunities for Manufacturers

The global drug-device combination products market has been classified into drug eluting stents, infusion pumps, photosensitizers, orthopedic combination products, wound care combination products, inhalers, transdermal patches, and others. Transdermal patches are projected to be the most popular products in the upcoming years. This is due to increase in demand for self-administered drugs for diseases that require long-term treatment. Rising geriatric population across the globe is also creating value-grab opportunities for the companies operating in the drug device combination products market.

Insulin must be administered intravenously to diabetic patients on a regular basis. Repeated use of injections to deliver insulin causes pain and increases the risk of infection transmission. Hence, alternative drug delivery modes are expected to gain popularity. Drug-device combination products offer several advantages, which include reduced adverse side effects, improved patient compliance, controlled release administration of drug, and provide targeted drug delivery.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Launch and Approval of Novel Drug-device Combination Products Boost Market Growth

Drug-device combination products are defined as individual products comprising two regulated components, an active pharmaceutical ingredient and medical device that are chemically or physically combined to produce a single product. The drugs present in the device are either impregnated or surface coated. Such products can be designed for local as well as systemic administration of drug to the patient. Key players in the global drug-device combination products market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global market during the forecast period. Recently, combination products are emerging as innovative medical products due to their contribution in advancing medical care and are, thus, projected to have a major impact in the upcoming years.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Drug-device Combination Products Market

Potential Growth Opportunities for Drug-device Combination Products Market Players in North America

North America is expected to account for the largest share of the global drug-device combination products market. The North America market is significantly driven by rise in incidence of chronic diseases such as diabetes, cancer, and respiratory problems, increase in casualties, owing to accidents and trauma, and rise in geriatric population. Asia Pacific is also considered as the most lucrative market for drug-device combination products due to increase in incidences of cardiovascular diseases, diabetes-related disorders, and obesity. Moreover, improving healthcare infrastructure and high market potential in untapped emerging economies are anticipated to provide lucrative growth opportunities for Asia Pacific market players.

However, factors, such as unnoticed complications of drug-device combination products, number of product recalls, and stringent government regulations hamper market growth.

Drug-device Combination Products Market: Overview

  • According to Transparency Market Research’s latest report on the global drug-device combination products market for the historical period, 2017–2019, and forecast period from 2021 to 2028, increase in geriatric population and technological advancements in drug delivery systems are projected to boost the growth of the global market during the forecast period

Rise in Prevalence of Chronic Diseases such as Diabetes, Respiratory Diseases, and Cancer: Key Driver

  • Rise in prevalence of chronic diseases and disorders such as cancer, cardiac conditions, multiple sclerosis, and diabetes is expected to fuel market growth
  • According to the National Center for Biotechnology Information (NCBI), around 126 million people (1,655 per 100,000) suffered from ischemic heart disease in 2017, accounting for 1.72% of the global population
  • Increase in the geriatric population is likely to fuel the growth of the global market during the forecast period. According to the United States Census Bureau, the geriatric population in the U.S. is projected to reach 77 million by 2034.

Risk of Infections and Strict Regulations on Drug-device Combination Products: Key Restraint

  • Drug-device combination products increase the risk of infection, which is anticipated to hamper market growth. Stent infection is uncommon; however, it is associated with significant morbidity and mortality.
  • Presence of a strict and non-specific regulatory pathway for drug-device combination product approval is expected to restrain the global market. In the U.S., pharmaceutical products and medical devices have separate regulatory approval pathways. Pharmaceutical products use the investigational new drug (IND) application process, while medical devices use the investigational device exemption (IDE) pathway.

Drug-device Combination Products Market: Competitive Landscape

  • This report profiles major players in the global drug-device combination products market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global drug-device combination products market is quite competitive, with the top ten players accounting for major share of the market and companies focusing on research & development to develop better pharmaceutical and vaccine products for the existing diseases
  • Leading players operating in the global drug-device combination products market are
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie, Inc.
    • Abbott Laboratories
    • Medtronic plc
    • Kaleo
    • SINOMED, Alcon, Inc.
    • Boston Scientific Corporation
    • Integer Holdings Corporation
    • Teleflex Incorporated
    • Bausch Health Companies, Inc.
    • Haselmeier GmbH
    • Flowonix Medical, Inc.

Drug-device Combination Products Market: Key Developments

  • Key players in the global drug-device combination products market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global drug-device combination products market. A few expansion strategies adopted by players operating in the global drug-device combination products market are:
    • In August 2020, Teva Pharmaceutical Industries Ltd. made its generic version of Mylan's EpiPen for children available in most retail pharmacies
    • In February 2020, Flowonix Medical, Inc. received the FDA approval for its Prometra II Programmable Pump System for use with intrathecal baclofen. The Prometra II Pump employs a pressure-driven, valve-gated delivery mechanism to deliver medication boluses into the intrathecal space.
  • The report on the global drug-device combination products market discusses individual strategies, followed by company profiles of manufacturers of drug-device combination products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global drug-device combination products market.

Drug-device Combination Products Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 120 Bn

Market Forecast Value in 2028

US$ 221 Bn

Growth Rate (CAGR)

7.3%

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

Product type

  • Drug Eluting Stents
    • Coronary Stents
    • Peripheral Vascular Stents
  • Infusion Pumps
    • Implantable Infusion Pumps
    • Ambulatory Infusion Pumps
  • Photosensitizers
  • Orthopedic Combination Products
    • Bone Graft Implants
    • Antibiotic Loaded Bone Cement
  • Wound Care Combination Products
  • Inhalers
    • Metered Dose Inhalers
    • Dry Powder Inhalers
    • Nebulizers
  • Transdermal Patches
  • Others
    • Intraocular Implants
    • Drug Eluting Beads

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Abbott Laboratories
  • Medtronic plc
  • Kaleo, Inc.
  • SINOMED
  • Alcon, Inc.
  • Boston Scientific Corporation
  • Integer Holdings Corporation
  • Teleflex Incorporated
  • Bausch Health Companies, Inc.
  • Haselmeier GmbH
  • Flowonix Medical, Inc.
  • Others

Customization Scope

Available upon request

Pricing

Available upon request

Drug-device Combination Products Market – Segmentation

Product Type
  • Drug Eluting Stents
    • Coronary Stents
    • Peripheral Vascular Stents
  • Infusion Pumps
    • Implantable Infusion Pumps
    • Ambulatory Infusion Pumps
  • Photosensitizers
  • Orthopedic Combination Products
    • Bone Graft Implants
    • Antibiotic Loaded Bone Cement
  • Wound Care Combination Products
  • Inhalers
    • Metered Dose Inhalers
    • Dry Powder Inhalers
    • Nebulizers
  • Transdermal Patches
  • Others
    • Intraocular Implants
    • Drug Eluting Beads
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Drug-device combination products market is expected to reach the value of US$ 221 Bn by the end of 2028

Drug-device combination products market is estimated to expand at a CAGR of 7.3% from 2021 to 2028

Drug-device combination products market is driven by high incidence rates of chronic pain causing diseases

North America is expected to account for the largest share of the global drug-device combination products market

Key players in the global drug-device combination products market include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Abbott Laboratories, Medtronic plc, Kaleo, SINOMED

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug-device Combination Products Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Drug-device Combination Products Market Analysis and Forecast, 2017-2028

5. Key Insights

    5.1. Key Mergers & Acquisitions

    5.2. Technological Advancements

    5.3. Covid19 Impact Analysis

    5.4. Regulatory Scenario by Region/globally

6. Global Drug-device Combination Products Market Analysis and Forecast, by Product Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product Type, 2017-2028

        6.3.1. Drug Eluting Stents

            6.3.1.1. Coronary Stents

            6.3.1.2. Peripheral Vascular Stents

        6.3.2. Infusion Pumps

            6.3.2.1. Implantable Infusion Pumps

            6.3.2.2. Ambulatory Infusion Pumps

        6.3.3. Inhalers

            6.3.3.1. Metered Dose Inhalers

            6.3.3.2. Dry Powder Inhalers

            6.3.3.3. Nebulizers

        6.3.4. Orthopedic Combination Products

            6.3.4.1. Bone Graft Implants

            6.3.4.2. Antibiotic Loaded Bone Cement

        6.3.5. Wound Care Combination Products

        6.3.6. Photosensitizers

        6.3.7. Others

    6.4. Market Attractiveness Analysis, by Product Type

7. Global Drug-device Combination Products Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Market Value Forecast, by Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Region

8. North America Drug-device Combination Products Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value Forecast, by Product Type, 2017-2027

        8.2.1. Drug Eluting Stents

            8.2.1.1. Coronary Stents

            8.2.1.2. Peripheral Vascular Stents

        8.2.2. Infusion Pumps

            8.2.2.1. Implantable Infusion Pumps

            8.2.2.2. Ambulatory Infusion Pumps

        8.2.3. Inhalers

            8.2.3.1. Metered Dose Inhalers

            8.2.3.2. Dry Powder Inhalers

            8.2.3.3. Nebulizers

        8.2.4. Orthopedic Combination Products

            8.2.4.1. Bone Graft Implants

            8.2.4.2. Antibiotic Loaded Bone Cement

        8.2.5. Wound Care Combination Products

        8.2.6. Photosensitizers

        8.2.7. Others

    8.3. Market Value Forecast by Country, 2017-2027

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Product Type

        8.4.2. By Country

9. Europe Drug-device Combination Products Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Product Type, 2017-2027

        9.2.1. Drug Eluting Stents

            9.2.1.1. Coronary Stents

            9.2.1.2. Peripheral Vascular Stents

        9.2.2. Infusion Pumps

            9.2.2.1. Implantable Infusion Pumps

            9.2.2.2. Ambulatory Infusion Pumps

        9.2.3. Inhalers

            9.2.3.1. Metered Dose Inhalers

            9.2.3.2. Dry Powder Inhalers

            9.2.3.3. Nebulizers

        9.2.4. Orthopedic Combination Products

            9.2.4.1. Bone Graft Implants

            9.2.4.2. Antibiotic Loaded Bone Cement

        9.2.5. Wound Care Combination Products

        9.2.6. Photosensitizers

        9.2.7. Others

    9.3. Market Value Forecast, by Country/Sub-region, 2017-2027

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Product Type

        9.4.2. By Country

10. Asia Pacific Drug-device Combination Products Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Product Type, 2017-2027

        10.2.1. Drug Eluting Stents

            10.2.1.1. Coronary Stents

            10.2.1.2. Peripheral Vascular Stents

        10.2.2. Infusion Pumps

            10.2.2.1. Implantable Infusion Pumps

            10.2.2.2. Ambulatory Infusion Pumps

        10.2.3. Inhalers

            10.2.3.1. Metered Dose Inhalers

            10.2.3.2. Dry Powder Inhalers

            10.2.3.3. Nebulizers

        10.2.4. Orthopedic Combination Products

            10.2.4.1. Bone Graft Implants

            10.2.4.2. Antibiotic Loaded Bone Cement

        10.2.5. Wound Care Combination Products

        10.2.6. Photosensitizers

        10.2.7. Others

    10.3. Market Value Forecast, by Country/Sub-region, 2017-2027

        10.3.1. Japan

        10.3.2. China

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Product Type

        10.4.2. By Country

11. Latin America Drug-device Combination Products Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product Type, 2017-2027

        11.2.1. Drug Eluting Stents

            11.2.1.1. Coronary Stents

            11.2.1.2. Peripheral Vascular Stents

        11.2.2. Infusion Pumps

            11.2.2.1. Implantable Infusion Pumps

            11.2.2.2. Ambulatory Infusion Pumps

        11.2.3. Inhalers

            11.2.3.1. Metered Dose Inhalers

            11.2.3.2. Dry Powder Inhalers

            11.2.3.3. Nebulizers

        11.2.4. Orthopedic Combination Products

            11.2.4.1. Bone Graft Implants

            11.2.4.2. Antibiotic Loaded Bone Cement

        11.2.5. Wound Care Combination Products

        11.2.6. Photosensitizers

        11.2.7. Others

    11.3. Market Value Forecast, by Country/Sub-region, 2017-2027

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Product Type

        11.4.2. By Country

12. Middle East & Africa Drug-device Combination Products Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast by Product Type, 2017-2027

        12.2.1. Drug Eluting Stents

            12.2.1.1. Coronary Stents

            12.2.1.2. Peripheral Vascular Stents

        12.2.2. Infusion Pumps

            12.2.2.1. Implantable Infusion Pumps

            12.2.2.2. Ambulatory Infusion Pumps

        12.2.3. Inhalers

            12.2.3.1. Metered Dose Inhalers

            12.2.3.2. Dry Powder Inhalers

            12.2.3.3. Nebulizers

        12.2.4. Orthopedic Combination Products

            12.2.4.1. Bone Graft Implants

            12.2.4.2. Antibiotic Loaded Bone Cement

        12.2.5. Wound Care Combination Products

        12.2.6. Photosensitizers

        12.2.7. Others

    12.3. Market Value Forecast, by Country/Sub-region, 2017-2027

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Product Type

        12.4.2. By Country

13. Competition Landscape

    13.1. Market Player - Competition Matrix (by tier and size of companies)

    13.2. Market Share Analysis, by Company, 2020

    13.3. Company Profiles

        13.3.1. Teva Pharmaceutical Industries Ltd.

            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.1.2. Financial Analysis

            13.3.1.3. Growth Strategies

            13.3.1.4. SWOT Analysis

        13.3.2. AbbVie, Inc.

            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2.2. Financial Analysis

            13.3.2.3. Growth Strategies

            13.3.2.4. SWOT Analysis

        13.3.3. Abbott Laboratories

            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.3.2. Financial Analysis

            13.3.3.3. Growth Strategies

            13.3.3.4. SWOT Analysis

        13.3.4. Medtronic plc

            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.4.2. Financial Analysis

            13.3.4.3. Growth Strategies

            13.3.4.4. SWOT Analysis

        13.3.5. Kaleo, Inc.

            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.5.2. Financial Analysis

            13.3.5.3. Growth Strategies

            13.3.5.4. SWOT Analysis

        13.3.6. SINOMED

            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.6.2. Financial Analysis

            13.3.6.3. Growth Strategies

            13.3.6.4. SWOT Analysis

        13.3.7. Alcon, Inc.

            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.7.2. Financial Analysis

            13.3.7.3. Growth Strategies

            13.3.7.4. SWOT Analysis

        13.3.8. Boston Scientific Corporation

            13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.8.2. Financial Analysis

            13.3.8.3. Growth Strategies

            13.3.8.4. SWOT Analysis

        13.3.9. Integer Holdings Corporation

            13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.9.2. Financial Analysis

            13.3.9.3. Growth Strategies

            13.3.9.4. SWOT Analysis

        13.3.10. Teleflex Incorporated

            13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.10.2. Financial Analysis

            13.3.10.3. Growth Strategies

            13.3.10.4. SWOT Analysis

        13.3.11. Bausch Health Companies Inc

            13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.11.2. Financial Analysis

            13.3.11.3. Growth Strategies

            13.3.11.4. SWOT Analysis

        13.3.12. Haselmeier GmbH

            13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.12.2. Financial Analysis

            13.3.12.3. Growth Strategies

            13.3.12.4. SWOT Analysis

List of Tables

Table 01: Global Drug-device Combination Products Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 02: Global Drug-device Combination Products Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 03: North America Drug-device Combination Products Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 04: North America Drug-device Combination Products Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 05: Europe Drug-device Combination Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 06: Europe Drug-device Combination Products Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 07: Asia Pacific Drug-device Combination Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 08: Asia Pacific Drug-device Combination Products Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 09: Latin America Drug-device Combination Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: Latin America Drug-device Combination Products Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

Table 11: Middle East & Africa Drug-device Combination Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Middle East & Africa Drug-device Combination Products Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

List of Figures

Figure 01: Global Drug-device Combination Products Market Value Share Analysis, by Product Type, 2021 and 2027

Figure 02: Global Drug-device Combination Products Market Attractiveness Analysis, by Product Type, 2021–2027

Figure 03: North America Drug-device Combination Products Market Value (US$ Mn) Forecast, 2017–2027

Figure 04: North America Drug-device Combination Products Market Value Share Analysis, by Country, 2021 and 2027

Figure 05: North America Drug-device Combination Products Market Attractiveness Analysis, by Country, 2021–2027

Figure 06: North America Drug-device Combination Products Market Value Share Analysis, by Product Type, 2021 and 2027

Figure 07: North America Drug-device Combination Products Market Attractiveness Analysis, by Product Type, 2021–2027

Figure 08: Europe Drug-device Combination Products Market Value (US$ Mn) Forecast, 2017–2027

Figure 09: Europe Drug-device Combination Products Market Value Share Analysis, by Country/Sub-region, 2021 and 2027

Figure 10: Europe Drug-device Combination Products Market Attractiveness Analysis, by Country/Sub-region, 2021–2027

Figure 11: Europe Drug-device Combination Products Market Value Share Analysis, by Product Type, 2021 and 2027

Figure 12: Europe Drug-device Combination Products Market Attractiveness Analysis, by Product Type, 2021–2027

Figure 13: Asia Pacific Drug-device Combination Products Market Value (US$ Mn) Forecast, 2017–2027

Figure 14: Asia Pacific Drug-device Combination Products Market Value Share Analysis, by Country/Sub-region, 2021 and 2027

Figure 15: Asia Pacific Drug-device Combination Products Market Attractiveness Analysis, by Country/Sub-region, 2021–2027

Figure 16: Asia Pacific Drug-device Combination Products Market Value Share Analysis, by Product Type, 2021 and 2027

Figure 17: Asia Pacific Drug-device Combination Products Market Attractiveness Analysis, by Product Type, 2021–2027

Figure 18: Latin America Drug-device Combination Products Market Value Share Analysis, by Country/Sub-region, 2021 and 2027

Figure 19: Latin America Drug-device Combination Products Market Attractiveness Analysis, by Country/Sub-region, 2021–2027

Figure 20: Latin America Drug-device Combination Products Market Attractiveness Analysis, by Product Type, 2021–2027

Figure 21: Middle East & Africa Drug-device Combination Products Market Value Share Analysis, by Country/Sub-region, 2021 and 2027

Figure 22: Middle East & Africa Drug-device Combination Products Market Attractiveness Analysis, by Country/Sub-region, 2021–2027

Figure 23: Middle East & Africa Drug-device Combination Products Market Attractiveness Analysis, by Product, 2021–2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Drug Device Combination Products Market